NEW YORK – Dutch diagnostics company SkylineDx announced on Tuesday a partnership with the multiple myeloma department of Wuerzburg University Medical Center II in Germany to assess the company's MMprofiler diagnostic test.
The MMprofiler test is a microarray-based, gene-expression test for multiple myeloma based on a 92-gene signature called SKY92 for diagnosing patients in high and standard risk groups. The test runs on Thermo Fisher Scientific Affymetrix microarrays and is offered as a CE-IVD kit in Europe, and as a laboratory-developed test in the US.
The main goal of the study is to measure the reliability of the MMprofiler test in a real-world setting and compare it with the hospital's current clinical standard, Rotterdam, Netherlands-based SkylineDx said. Patients included in the study will be followed for five years. The study will also evaluate their responses to treatment.
"We know that high-risk disease in multiple myeloma needs to be treated differently and SKY92 GEP testing will help us to better identify such patients with aggressive disease," said Leo Rasche, one of the leaders of Wuerzburg's lab.
Last year, the firm partnered with the Mayo Clinic to introduce a new molecular test for primary cutaneous melanoma.